Announced today that the companys highly selective oral kinase inhibitor.

Work Biotech’s Telatinib receives orphan drug designation from FDA for treatment of gastric cancer Action Biotech Inc., a privately held biotechnology company creating a portfolio of oral kinase inhibitors mainly because anti-cancer medications, announced today that the company’s highly selective oral kinase inhibitor, Telatinib, offers received orphan drug designation from the U .S. Food and Medication Administration for the treatment of gastric cancer. Telatinib happens to be in Phase 2 medical testing in the usa and in European countries for the first-line treatment of advanced gastric cancers patients in conjunction with standard-of-care chemotherapy.

The award is made possible through a gift from Julius H. Jacobson II, MD, FACS, and his wife Joan. Dr. Jacobson is an over-all vascular surgeon known for his pioneering work in the development of microsurgery. Dr. Berci’s pioneering function in endoscopy and laparoscopy began with his studies in mechanical engineering, mostly of the educational possibilities to him in the pre-World War II-era in Hungary. Following time spent in a Nazi labor camp in the mountains of Romania and Poland during the war, he pursued his medical and medical training in Hungary.